Elaine Wynn, co-founder of Wynn Resorts (WYNN), sees both challenges and potential ahead for the gaming industry in the U.S. and abroad. Wynn, who also founded and led Mirage Resorts (MGM), spoke on the subject of resiliency at Fortune’s The Most Powerful Women Summit in Washington D.C. Her own career has had its ups and downs, including last spring’s public ouster from the board of directors of Wynn Resorts. Wynn said there are lessons learned from the career highs and lows. ‘Nothing is forever. And I think professional experiences mirror personal experiences as well. So as you live your life and you have crises, whether they are mini or major, you develop coping skills,’ said Wynn. On the gaming industry, Wynn said she still sees potential in the Macau market, which has recently been hit by a slump in casino revenues. ‘They’re gazillions of people in China, a wonderful new up and coming middle class that’s enjoying traveling. There are many choices in Macau other than gaming. So we’re very hopeful that the mass market will continue to develop and will be a very fertile piece of the business for us and for our colleagues,’ she said. But Wynn was pessimistic about the future of Atlantic City, where casinos have shuttered their doors.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.